lululemon athletica heads into Wednesday's Q2 print with short interest at a six-month high, a 5% single-day bounce still fresh, and the Street broadly neutral but trimming targets — a setup that puts maximum pressure on the result itself.
Short sellers have added aggressively and kept adding. Short interest now stands at 10.2% of the free float, up 17.7% in a week and 16.5% over the past month — the fastest sustained build in more than six months. To put the scale in context: when LULU reported Q1 on June 4 and fell 9.4% in a day, SI was sitting at 6.3% of float. Bears have added roughly four percentage points of float exposure since that drop, with the sharpest acceleration arriving in the final days of this week. The ORTEX short score has climbed to 55.1 and has risen every day for the past ten sessions, signalling that the underlying momentum of the short position is still building rather than consolidating.
The borrow market, though, is not rationing supply. Availability — the ratio of shares still available to lend against those already borrowed — sits at 477%, well within normal territory despite the position build. Cost to borrow has risen 31% over the week to 0.48% APR and is up 65% over the past month, but that absolute level remains trivially cheap. There is no meaningful squeeze dynamic in the lending market right now: shorts are building because they want to, not because they're trapped. Options are similarly composed. The put/call ratio at 0.75 sits fractionally above its 20-day average of 0.75, with a z-score of just 0.58 — well within one standard deviation. Neither the options market nor the borrow market is flashing the kind of stress that would force a short-covering scramble.
The Street is broadly on the sidelines, and recent moves have tilted bearish on valuation even where ratings held steady. UBS cut its target to $120 from $124 this week — matching the current price almost exactly — while Morgan Stanley reinstated coverage at Underweight with a $93 target in early July and Truist downgraded to Sell, targeting $94. JP Morgan bucked the trend in early August, lifting its neutral target to $154, but that reading now sits well above where the consensus has congregated. The mean analyst target of $127 implies only about 5% upside from Friday's $120.81 close, and the distribution is wide. Factor scores reflect the same picture: EPS momentum over both 30-day (29th percentile) and 90-day (11th percentile) windows is weak, and the short score rank at the 14th percentile signals the stock is well into the bottom tier on bearish positioning metrics. The EV/EBITDA of 5.6x and PE near 10x are compressed, consistent with a market that is not paying for recovery yet.
The earnings history adds one clear data point worth noting. The last two LULU prints both resolved decisively. Q1 on June 4 delivered a 9.4% single-day drop and a 3.3% five-day loss. A guidance update event on June 25 went the other way, with a 4.0% day-one gain and 4.7% over five days. The stock does not tend to drift — it moves on the number. With SI at 10.2% of float and a 5% bounce already banked this week, the binary is sharply defined: a beat-and-raise compresses the short base rapidly given how cheap the borrow remains, while a miss hands bears one of their most favourable setups in months.
What to watch is simple: Wednesday's Q2 revenue and gross margin against the current subdued consensus, and whether management offers any clarity on the China recovery timeline and the product-refresh cycle that has been the central dispute between bulls and bears all year.
See the live data behind this article on ORTEX.
Open LULU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
